Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Empagliflozin Monotherapy vs Placebo and Sitagliptin in Drug-Naïve T2DM
NCT01177813Phase 3Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Jul 2010
- Primary completion
- Mar 2012
- Modality
- Small Molecules
- Countries
- 9
01
Overview
Phase 3, randomised, double-blind trial of empagliflozin in type 2 diabetes mellitus (T2DM) (5 arms), sponsored by Boehringer Ingelheim. Primary endpoint: Change From Baseline in Glycosylated Haemoglobin (HbA1c) at 24 weeks. Started Jul 2010; status: completed.
02
Drugs
empagliflozin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT01177813.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01177813.